This report will focus on some of the key studies in the field of digestive oncology, presented during the 2019 annual ESMO meeting. During the congress, many studies were presented from early phase I to large phase III trials. Different approaches to activate the immune system against tumours as well as PARP and CDK4/6 inhibitors were once more at the centre of interest for different types of cancer and settings.